Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay
Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...
Drug
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Receives FDA Clinical Trial Approval
Huadong Medicine Co., Ltd (SHE: 000963), a pharmaceutical company based in China, has announced that...
China’s Sichuan Huiyu Pharmaceutical Halts Generic Cytosar Launch Following Strategy Review
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced...
Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...
Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer
Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...
Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration
Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...
BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...
Staidson Pharmaceutical’s Bemiltenase Alfa Earns Orphan Drug Designation from US FDA for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...
Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...
CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis
Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...
Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...
Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...
Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...